Reversible memory loss in a mouse transgenic model of Alzheimer's disease - Wikidata - wikimedia - TriplyDB

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

http://www.wikidata.org/entity/Q28591326

about

Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease Pathways towards and away from Alzheimer's disease Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior Active and passive immunotherapy for neurodegenerative disorders Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease.Non-steroidal anti-inflammatory drugs and cognitive function: are prostaglandins at the heart of cognitive impairment in dementia and delirium?Alzheimer's therapeutics: translation of preclinical science to clinical drug development Structural Correlates of Antibodies Associated with Acute Reversal of Amyloid -related Behavioral Deficits in a Mouse Model of Alzheimer Disease Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies ACAT1/SOAT1 as a therapeutic target for Alzheimer's disease Ferulic acid is a nutraceutical β-secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice Disease modifying therapies for Alzheimer's disease targeting Aβ oligomers: implications for therapeutic mechanisms Extracellular and intraneuronal HMW-AbetaOs represent a molecular basis of memory loss in Alzheimer's disease model mouse Amyloid-β oligomer specificity mediated by the IgM isotype--implications for a specific protective mechanism exerted by endogenous auto-antibodies Is glial heme oxygenase-1 suppression in neurodegenerative disorders permissive for neural repair?Phagocytic clearance in neurodegeneration.Type 2 diabetes and Alzheimer's disease: from common pathologies to potential new therapeutics.Reduced pathology and improved behavioral performance in Alzheimer's disease mice vaccinated with HSV amplicons expressing amyloid-beta and interleukin-4.Carvedilol as a potential novel agent for the treatment of Alzheimer's disease.Chronic zinc exposure decreases the surface expression of NR2A-containing NMDA receptors in cultured hippocampal neurons.Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice.Beneficial catalytic immunity to abeta peptide.Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer's disease Genetic modulation of soluble Aβ rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine.An update on the amyloid hypothesis.Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model.Nanoscience enables ultrasensitive detection of Alzheimer's biomarker Tg2576 cortical neurons that express human Ab are susceptible to extracellular Aβ-induced, K+ efflux dependent neurodegeneration Neuroinflammation and related neuropathologies in APPSL mice: further value of this in vivo model of Alzheimer's disease.Amyloid-beta immunotherapy for Alzheimer's disease An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies Drug development for Alzheimer's disease: where are we now and where are we headed?Probing the biology of Alzheimer's disease in mice.Unintended effects of cardiovascular drugs on the pathogenesis of Alzheimer's disease

P2860

8828241ec65341e85a6786319f994ee1d03a1591

P248

Q21144713-7FED2CAC-9206-4AFE-B9E1-5AA0C93CDF31 Q24534813-26279276-2AE7-4CDA-B444-781D36BE645C Q24596270-164C78F0-E850-402B-9E58-D86AEDDAD517 Q24645994-55C32D96-20D2-497B-9A92-6A97A97292B4 Q24657879-EABDB238-8B3B-4339-9390-5F577065437B Q24675823-97938AB4-C1FB-49F0-A3CA-55E79BD8559F Q24791704-E437FE79-DE3E-4DCF-99A7-6221512EA9C6 Q25256570-0FB2EE6C-7B5D-4B13-AC5D-B068B3DF98BA Q26822022-1B622845-41AB-4A9E-A06B-656584EF8622 Q26829267-B5A6F238-3668-4687-AE02-D5D63B7A1B0F Q27658233-D651EA2A-E33D-45BE-9882-929D6AB0684C Q28069362-F7A4E761-162C-42AC-8AB2-6D7C56E73115 Q28081654-824E6F46-40ED-4918-B740-A79A8897C818 Q28486102-DD5329C7-375B-404B-A292-5A9D2A535306 Q28680809-427A553D-9817-487C-8020-266B91A4ECA5 Q28741744-FE398F14-506E-40B5-939B-E1271B46EA79 Q28748498-78660F2B-0D23-450F-8CDF-A0CF7D7E1969 Q30414246-52C20AEA-5BCB-439C-80ED-D784A0AEE2F6 Q30427542-A76D9804-9E2C-40F5-8E58-B4D04B7B68BE Q30438004-7168DCB9-CE90-4370-B8BC-09F92D835FDD Q30482492-B760B920-62D3-4762-8059-687E7C915559 Q30497187-BD13739F-AB33-40B1-A9A4-FDA4605590FE Q31103465-B3BCFAD7-50FB-4F36-ABAA-D658D883A55C Q33291589-7FC67795-E185-41E2-AC1A-51C7D3B7A612 Q33549900-98BA6B2F-CC41-40E4-BD57-8E7EE3536974 Q33572338-D6658BA9-BDAE-4601-AFC1-4FB57AD68BB1 Q33582089-9D91D263-F724-4764-8682-5BCEFFC29FE4 Q33707872-3E54BA83-E84E-42B3-8C9F-5B1A76FF2907 Q33742312-B5AEBB76-68D0-47E3-9019-2045500315C5 Q33800962-BD282308-CCDC-431D-82A9-89CCF1C8FF37 Q33808402-6C697A32-1B99-414B-8460-D7B3E33F92DB Q33810933-5BCC31FC-08AF-4221-A50F-DE36546DB599 Q33850570-FCD74625-BFCA-4EE6-A966-B46D119C3630 Q33893757-4E181BE0-AA46-47DB-94DC-53DDE739D4E4 Q33939172-E56820C7-7568-4303-ACCF-B77A8DB80225 Q33954737-1B9C79EC-4DC9-4403-BFDD-A9A36535848F Q33988301-FDF9D3DD-B2DC-4ED9-99F3-CD1D0E919830 Q34166256-AA3B894C-0859-4FE8-A4A6-C91AA0565CCD Q34206962-6BFAA1AB-24F0-4BE9-AE75-174F962F9FBD Q34350595-8DAF089C-1F9D-43C0-96DA-DE53EE9CDB13

P2860

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

http://www.wikidata.org/entity/Q28591326

description

2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

artículu científicu espublizáu en 2002

@ast

im August 2002 veröffentlichter wissenschaftlicher Artikel

@de

scientific journal article

@en

vedecký článok (publikovaný 2002/08/01)

@sk

vědecký článek publikovaný v roce 2002

@cs

wetenschappelijk artikel (gepubliceerd op 2002/08/01)

@nl

наукова стаття, опублікована в серпні 2002

@uk

مقالة علمية (نشرت في أغسطس 2002)

@ar

name

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

@ast

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

@en

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

@nl

type

label

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

@ast

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

@en

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

@nl

prefLabel

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

@ast

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

@en

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

@nl

P1433

Q28591326-29875F58-0CD1-43BE-9520-E960F898FCF2

P1476

Q28591326-227E478B-9F91-4097-ACF7-5D9F13FECEAF

P2093

Q28591326-2ED4CDFB-942D-44F0-93D5-6B3D7630D793

Q28591326-7BB1B3F2-3D15-4A34-B063-39047B4090BB

Q28591326-7EA92580-2E93-48AD-99D1-D64E1B5F47F7

Q28591326-852F7E81-D969-4FC0-A52C-698B9BF6E9F5

Q28591326-8B95D8E7-0111-40D2-A1BE-A4F3E7A7760F

Q28591326-9275DF41-BE8A-4E3C-BBA4-66D52EBD014B

Q28591326-D488B23F-1E70-4739-BD4B-9BF242E87D60

Q28591326-E9FCD672-F228-43C7-9004-17786E711617

P304

Q28591326-3280F535-21F6-4984-AF37-14CE2D650F05

P31

Q28591326-51429417-D9A1-45E6-A1E4-690A867EA0A3

P3181

Q28591326-D27CBD39-5263-408D-8976-5AE12C106187

P356

Q28591326-6120963C-D463-41C3-9010-E847DE4A6C75

P407

Q28591326-715A107D-60E3-43C7-ABEB-9D1A58F4E182

P433

Q28591326-0D6F20DF-BFAA-4222-AF4D-215013EB107D

P478

Q28591326-DC68AB6E-38FF-4381-B7F0-6802686DE33C

P50

Q28591326-C78F66B0-B76E-4FE4-B6B6-DF39B92455B5

P577

Q28591326-DF30FCF5-DB34-4C2A-81E3-8DA63CD7ACB3

P698

Q28591326-67DEDE5B-41D1-4D0F-A805-FABF93CE642B

P921

Q28591326-06A199A6-EB87-42C3-92F6-DD30839481F6

P932

Q28591326-C5A17CCE-1038-4AC5-AB7B-439E0A88C1B7

P3181

P356

JNEUROSCI.22-15-06331.2002

P1433

Journal of Neuroscience

P1476

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

@en

P2093

Bradley T Hyman

http://www.w3.org/2001/XMLSchema#string

Brian Bacskai

http://www.w3.org/2001/XMLSchema#string

Karen H Ashe

http://www.w3.org/2001/XMLSchema#string

Linda A Kotilinek

http://www.w3.org/2001/XMLSchema#string

Linda Younkin

http://www.w3.org/2001/XMLSchema#string

Marcus Westerman

http://www.w3.org/2001/XMLSchema#string

Steven Younkin

http://www.w3.org/2001/XMLSchema#string

Takeshi Kawarabayashi

http://www.w3.org/2001/XMLSchema#string

P304

6331-6335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2220877

http://www.w3.org/2001/XMLSchema#string

P356

10.1523/JNEUROSCI.22-15-06331.2002

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12151510

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

6758140

http://www.w3.org/2001/XMLSchema#string